US2018147272A1PendingUtilityA1

Vaccine Candidates Against Johne's Disease

64
Assignee: WISCONSIN ALUMNI RES FOUNDPriority: Dec 9, 2005Filed: Nov 29, 2017Published: May 31, 2018
Est. expiryDec 9, 2025(expired)· nominal 20-yr term from priority
Inventors:Adel M. Talaat
A61K 2039/552A61K 2039/53A61K 39/04A61K 39/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, or map1634 of M. paratuberculosis and their products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis -specific genomic islands (MAPs) were identified. Three inverted large genomic fragments in M. paratuberculosis (INV) were also identified. These genomic identifiers represent novel virulence determinants that can be used as targets for vaccines and for developments of drugs against Johne's disease. The method can be used to deliver an immunizing compounds to a mammal, to provide an immune response against Johne's or Crohn's disease in the mammal.

Claims

exact text as granted — not AI-modified
1 . A vaccine composition comprising:
 a) an antigen selected from the group comprising gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, or map1634 genes of  M. paratuberculosis  or their homologs; and   b) a pharmaceutically acceptable carrier.   
     
     
         2 . The vaccine composition of  claim 1  further comprising an adjuvant. 
     
     
         3 . A vaccine composition comprising:
 a) an antigen selected from the group comprising MAP-1, MAP-2, MAP-3, MAP-4, MAP-5, MAP-6, MAP-7, MAP-8, MAP-9, MAP-10, MAP-11, MAP-12, MAP-13, MAP-14, MAP-15, MAP-16, MAP-17, or MAP-18 genomic islands of  M. paratuberculosis  or their homologs; and   b) a pharmaceutically acceptable carrier.   
     
     
         4 . The vaccine composition of  claim 3  further comprising an adjuvant. 
     
     
         5 . An immunological composition comprising:
 a) a eukaryotic expression vector comprising a nucleotide sequence encoding an antigen selected from the group comprising gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, or map1634 genes of  M. paratuberculosis  or their homologs; and   b) a pharmaceutically acceptable carrier.   
     
     
         6 . The immunological composition of  claim 5  further comprising an adjuvant. 
     
     
         7 . An immunological composition comprising:
 a) a eukaryotic expression vector comprising a nucleotide sequence encoding an antigen selected from the group comprising MAP-1, MAP-2, MAP-3, MAP-4, MAP-5, MAP-6, MAP-7, MAP-8, MAP-9, MAP-10, MAP-11, MAP-12, MAP-13, MAP-14, MAP-15, MAP-16, MAP-17, or MAP-18 genomic islands of  M. paratuberculosis  or their homologs; and   b) a pharmaceutically acceptable carrier.   
     
     
         8 . The immunological composition of  claim 7  further comprising an adjuvant. 
     
     
         9 . A method of treating Johne's disease, comprising administering to a mammal a vaccine composition according to  claim 1 . 
     
     
         10 . The method of  claim 9  further comprising administering an adjuvant. 
     
     
         11 . The method of  claim 9  wherein the mammal is selected from the group consisting of a porcine, bovine, equine, feline, canine, pig, cow, primate, reptile, rodent, and deer. 
     
     
         12 . The method of  claim 9  wherein the vaccine composition is administered by parenteral injection. 
     
     
         13 . A method of treating Johne's disease, comprising administering to a mammal a vaccine composition according to  claim 3 . 
     
     
         14 . The method of  claim 13  further comprising administering an adjuvant. 
     
     
         15 . The method of  claim 13  wherein the mammal is selected from the group consisting of a porcine, bovine, equine, feline, canine, pig, cow, primate, reptile, rodent, and deer. 
     
     
         16 . The method of  claim 13  wherein the vaccine composition is administered by parenteral injection. 
     
     
         17 . A method of treating Johne's disease, comprising administering to a mammal an immunological composition against  M. paratuberculosis  according to  claim 5 . 
     
     
         18 . The method of  claim 17  further comprising administering an adjuvant. 
     
     
         19 . The method of  claim 17  wherein the mammal is selected from the group consisting of a porcine, bovine, equine, feline, canine, pig, cow, primate, reptile, rodent, and deer. 
     
     
         20 . The method of  claim 17  wherein the vaccine composition is administered by parenteral injection. 
     
     
         21 . A method of treating Johne's disease, comprising administering to a mammal an immunological composition against  M. paratuberculosis  according to  claim 7 . 
     
     
         22 . The method of  claim 21  further comprising administering an adjuvant. 
     
     
         23 . The method of  claim 21  wherein the mammal is selected from the group consisting of a porcine, bovine, equine, feline, canine, pig, cow, primate, reptile, rodent, and deer. 
     
     
         24 . The method of  claim 21  wherein the vaccine composition is administered by parenteral injection.

Join the waitlist — get patent alerts

Track US2018147272A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.